title: Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review.
abstract: Moderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects on cardiovascular and liver health are unclear. Moderate alcohol use is associated with improved insulin sensitivity and decreased cardiovascular mortality in the general population, but whether similar benefits would be observed in persons with NAFLD remains largely unstudied. There is significant overlap in the pathogenesis of alcoholic liver disease (ALD) and NAFLD, although studies of ALD have focused on pathological alcohol intake and few mechanistic studies of moderate alcohol use in NAFLD exist. We undertook a critical review of the effect of moderate alcohol use on cardiovascular and liver disease in patients with NAFLD. A total of seven observational studies met the criteria for inclusion (one for cardiovascular endpoints and six for liver endpoints). Insufficient studies have assessed the association of moderate alcohol use with cardiovascular outcomes. There was a positive association between moderate alcohol use and decreased NASH and fibrosis; however, heavy episodic drinking may accelerate fibrosis progression and moderate alcohol use may increase the risk of hepatocellular carcinoma in patients with advanced fibrosis. Significant methodological limitations were present, including incomplete adjustment for confounding factors and failure to measure lifetime use or the pattern of alcohol intake. Thus, a strong recommendation of benefit of moderate alcohol use in NAFLD cannot be made. There remains a need for additional high-quality longitudinal studies that evaluate both cardiovascular and liver outcomes among NAFLD patients with moderate or lesser degrees of alcohol use. (Hepatology 2017;65:2090-2099).
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA.
authors.forename: Veeral H
authors.initials: VH
authors.lastname: Ajmera
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA.
authors.forename: Norah A
authors.initials: NA
authors.lastname: Terrault
authors.affiliation: Division of Gastroenterology, Department of Medicine, San Antonio Military Medical Center, Fort Sam Houston, TX.
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Harrison
mesh_terms: D000428:Alcohol Drinking / Q000009:adverse effects*; D001707:Biopsy, Needle; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008108:Liver Diseases, Alcoholic / Q000473:pathology* / Q000503:physiopathology; D008113:Liver Neoplasms / Q000473:pathology* / Q000503:physiopathology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D020380:Needs Assessment; D065626:Non-alcoholic Fatty Liver Disease / Q000473:pathology* / Q000503:physiopathology; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index